Eugonda Fryman, APRN
Family · Cynthiana, KYNPI 1083020853
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $11,900 of the $13,241 with a category attached, or 89.9%. Insulet Corporation accounts for 92.7% of it on its own, with 21 other manufacturers making up the rest. 2025 is the largest year on record at $6,168, more than ten times the $542 reported in 2021. Among family clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 79 payments — averaging $167.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$12K
- Bayer$175
- Dexcom, Inc.$140
- Teva Pharmaceuticals USA, Inc.$110
- AbbVie$92
- Novo Nordisk$66
- plus $389 from 16 others
What the payments were for
- Speaking & faculty fees$11,90090%
- Food & beverage$1,34110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insulet Corporation | 33 | $12,268 |
| Bayer | 5 | $175 |
| Dexcom, Inc. | 4 | $140 |
| Teva Pharmaceuticals USA, Inc. | 7 | $110 |
| AbbVie | 4 | $92 |
| Novo Nordisk | 3 | $66 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $64 |
| Astellas Pharma US Inc | 2 | $42 |
| Abbott | 2 | $39 |
| Medtronic | 2 | $38 |
| GSK | 2 | $33 |
| Corcept Therapeutics | 2 | $31 |
| Novartis | 1 | $20 |
| Lilly USA, LLC | 1 | $17 |
| Pfizer | 1 | $16 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Merck | 1 | $12 |
| Eisai Inc. | 1 | $12 |
| Boehringer Ingelheim | 1 | $12 |
| AstraZeneca | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,241 in reported general payments places this provider in the 95th percentile of 4,374 family providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 61 | $56,225 |
| MounjaroTirzepatide | 42 | $43,281 |
| JardianceEmpagliflozin | 37 | $35,388 |
| TrulicityDulaglutide | 30 | $32,247 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 48 | $30,405 |
| XareltoRivaroxaban | 14 | $15,400 |
| FarxigaDapagliflozin Propanediol | 18 | $15,228 |
| EliquisApixaban | 14 | $14,389 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $12,935 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 22 | $11,163 |
| TradjentaLinagliptin | 11 | $9,471 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $7,978 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 17 | $7,755 |
| Tetrabenazine | 12 | $4,487 |
| Mesalamine | 12 | $2,361 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Insulin Lispro | $17 | $77,22496 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta, Stiolto Respimat | $12 | $63,77787 claims |
| Novo NordiskOzempic, Novolog | $66 | $58,31476 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $33 | $20,91435 claims |
| AstraZenecaFarxiga | $11 | $15,22818 claims |
| PfizerEliquis | $16 | $14,38914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,374 family providers in Kentucky.
Other family in Cynthiana
- Bonnie HillLouisa$372K
- Ashley SnellenElizabethtown$190K
- Smita RanjanLouisville$92K
- Tracey GaslinLouisville$79K
- Kassandra GreenLouisville$69K
- Danielle RevertLouisville$65K
- Lora BrownMonticellow$61K
- Shelley WaldmanLouisville$59K
- Vicki ChapmanMount Vernon$57K
- Carrie Parrish NyekanBowling Green$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.